Rosen Law Firm Encourages Biohaven Ltd. Investors to Assert Their Rights

Rosen Law Firm, a leader in investor rights advocacy, has recently made an announcement aimed at shareholders of Biohaven Ltd. (NYSE: BHVN). A class action lawsuit has been filed on behalf of individuals who acquired Biohaven securities between March 24, 2023, and May 14, 2025. Investors within this time frame are urged to take action if they wish to assert their rights and potentially recover damages.

Details of the Class Action Lawsuit

As reported, the class action lawsuit stems from alleged misleading statements made by the company regarding its products and the overall financial health of Biohaven. The claims include that the regulatory prospects of the drug troriluzole, aimed at treating spinocerebellar ataxia (SCA), were overstated. Furthermore, the lawsuit asserts that the company's claims concerning the efficacy of BHV-7000 in treating bipolar disorder were similarly inflated. Such misrepresentations, once brought to light, are believed to have severely impacted the company’s market performance and financial standing, ultimately leading to investor losses.

If you purchased Biohaven securities during the class period, you may indeed have the right to a claim without incurring out-of-pocket costs, as Rosen Law operates on a contingency fee basis. Investors are encouraged to act quickly because you must file to serve as lead plaintiff by September 12, 2025. A lead plaintiff plays a crucial role by representing the interests of other shareholders in the ongoing litigation.

Steps to Join the Class Action

For those wishing to be a part of the class action, there are clear steps to follow. Interested investors can go to the Rosen Law Firm's dedicated webpage or reach out directly to their legal team. Specifically, Phillip Kim, an attorney with the firm, is available at 866-767-3653 or via email at [email protected] This direct outreach can provide potential plaintiffs with insightful information regarding their rights and the subsequent steps to take.

It’s important to note that the class has not yet been certified, meaning that until such certification occurs, participating investors are not formally represented unless they appoint their own counsel. Investors can, however, remain passive members of the class while retaining their eligibility to benefit from any future financial recoveries.

Why Choose Rosen Law Firm?

Rosen Law Firm is well-regarded for its experienced approach to securities class actions and shareholder derivative litigation. With a proud history of securing significant settlements, the firm emphasizes the importance of selecting qualified counsel for any legal matter. Highlighting its track record, the firm was noted for achieving the largest securities class action settlement against a Chinese company. The firm has consistently ranked among the top firms nationwide for securities settlements, securing over $438 million for investors in just 2019 alone.

The advocacy extends beyond just legal representation; it emphasizes educating investors about their rights and the value of experienced legal counsel. Laurence Rosen, a founding partner of the firm, has received numerous accolades within the legal community, reinforcing the firm's credibility and commitment to investor rights.

Staying Informed

For updates about the case and other similar initiatives, investors are encouraged to follow Rosen Law Firm on social media platforms such as LinkedIn, Twitter, and Facebook. This engagement can provide valuable insights into ongoing legal developments regarding investor rights and upcoming cases that may impact current and future shareholders.

In conclusion, if you are a shareholder of Biohaven Ltd., now is an opportune time to assess your position and consider joining the lawsuit to safeguard your rights. The path ahead is clear, and the Rosen Law Firm aims to provide the necessary support during this critical period for impacted investors.